tezepelumab
Sponsor Astrazeneca PLC · listed as AZN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
tezepelumab is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 7, 2027 (day precision, medium confidence), tied to trial NCT07363642. The asset is in Phase 3 and currently recruiting, studied in Severe Asthma. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-08-07
As disclosedAug 7, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT07363642
PhasePHASE3
StatusRECRUITING
Lead sponsorAstraZeneca
Listed asAZN
Condition(s)Severe Asthma
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More AZN catalysts